Molecular Targets in Cancer Therapy, Mechanism and Therapeutic Reversal of Immune Suppression in Cancer
Register now! Space is limited! Registration ends January 10th, 2007!
Important Conference Update Bulletin - December 19, 2006! Click here
Use the links below for more information about this event:
Course Overview
The international biomedical conference will be held January 25th - 28th, 2007 at the Sheraton Sand Key Hotel in Clearwater Beach, Florida. The purpose of this meeting is to foster exchange of the most recent findings and ideas in tumor immunology. Despite high promise, cancer immunotherapy so far has not delivered tangible clinical benefits. It is now clear that without understanding the mechanisms of tumor induced immune suppression, further progress in this area will not be possible. By this time, a large number of possible mechanisms of immune suppression in cancer have been proposed. They form a foundation for current and future clinical trials; however, this wealth of information has created a very convoluted picture. Proposed mechanisms compete with each other. There is a pressing need for the entire field to discuss already described and new emerging mechanisms to see how they can be put together in more or less cohesive structure. Special emphasis will be placed on new approaches to therapeutic correction of observed abnormalities.
The conference will include a keynote address, many plenary session lectures, workshops, poster session, a roundtable discussion, vendor exhibits and several meal functions. Time will be set aside for networking with colleagues around the world. This innovative and exciting program will be presented by leading experts in the field and will cover recent advances in cancer immunotherapy, as well as cellular and molecular mechanisms of tumor-induced tolerance and immune suppression. The translation of basic science discoveries from the laboratory bench to the treatment of cancer patients in the clinic will also be emphasized.
Program Objectives
As a result of participating in this educational program, participants will be able to:
- Assess recent progress in the filed of cancer immunotherapy;
- Review successes and failures of current immunotherapy regiments;
- Evaluate different mechanisms of tumor induced immune suppression;
- Discuss contribution of these mechanisms to failure of cancer treatment;
- Examine how different molecular pathways contribute to tumor escape of immune system control;
- Review and discuss how our knowledge of new mechanisms of tumor associated immune suppression can be translated into new therapeutics
Audience
This educational activity is planned to meet the educational needs of basic scientists and clinical investigators in both academia and industry who are interested in the development of novel immunotherapy in cancer therapeutics, as well as clinical oncologists, surgical oncologists, and pathologists. Attendees should be actively engaged in cancer research and/or clinical practice. Students specialized in cancer research and immunology are also encouraged to attend.
Accreditation
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of South Florida College of Medicine and H. Lee Moffitt Cancer Center & Research Institute.
The University of South Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The University of South Florida College of Medicine designates this educational activity for a maximum of 24.75 category 1 credits towards the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Nurses: The University of South Florida College of Nursing is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation. This activity is for 24.9 contact hours. Each nurse should claim only those hours of credit that he/she actually spent in the educational activity.
When
January 25-28, 2007
Planning Committee
The planning committee for the fourth biennial Molecular Targets in Cancer Therapy conference include:
- Dmitry Gabrilovich, M.D., Ph.D. - Chairman and Course Director
- Claudio Anasetti, M.D.
- Scott Antonia, M.D. Ph.D.
- Esteban Celis, M.D. Ph.D.
- Sophie Dessureault, M.D.
- Julie Djeu, Ph.D.
- Mary Dunn, RN
- Mayer Fishman, M.D., Ph.D.
- Alan List, M.D.
- James Mule, Ph.D.
- Raoul Salup, M.D.
- Andrew Sloan, M.D.
- Vernon Sondak, M.D.
- Eduardo Sotomayor, M.D., Ph.D.
For additional information on this conference:
Please click here to contact the conference coordinator with questions and/or to subscribe to the Molecular Targets in Cancer Therapy mailing list.